Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Lanar

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Vaccine|September 2, 2022
First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adultsJack N Hutter, Paul M Robben, Christine Lee, et al.
Malaria Journal|October 11, 2007
Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunizationGeorge Jiang, Yupin Charoenvit, Alberto Moreno, et al.
Vaccine|April 20, 2007
Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of ResearchMark E Polhemus, Alan J Magill, James F Cummings, et al.
Nature Communications|May 11, 2018
A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparumAlison Roth, Steven P Maher, Amy J Conway, et al.
Nature Communications|June 10, 2018
Author Correction: A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparumAlison Roth, Steven P Maher, Amy J Conway, et al.
Vaccine|September 10, 2009
Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infectionJames F Cummings, Michele D Spring, Robert J Schwenk, et al.
Plos One|April 25, 2009
Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02AMichele D Spring, James F Cummings, Christian F Ockenhouse, et al.
Plos One|January 24, 2008
Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trialMahamadou A Thera, Ogobara K Doumbo, Drissa Coulibaly, et al.
Plos One|February 9, 2010
Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trialMahamadou A Thera, Ogobara K Doumbo, Drissa Coulibaly, et al.
The New England Journal of Medicine|September 16, 2011
A field trial to assess a blood-stage malaria vaccineMahamadou A Thera, Ogobara K Doumbo, Drissa Coulibaly, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Vaccine|September 2, 2022
First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adultsJack N Hutter, Paul M Robben, Christine Lee, et al.
Malaria Journal|October 11, 2007
Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunizationGeorge Jiang, Yupin Charoenvit, Alberto Moreno, et al.
Vaccine|April 20, 2007
Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of ResearchMark E Polhemus, Alan J Magill, James F Cummings, et al.
Nature Communications|May 11, 2018
A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparumAlison Roth, Steven P Maher, Amy J Conway, et al.
Nature Communications|June 10, 2018
Author Correction: A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparumAlison Roth, Steven P Maher, Amy J Conway, et al.
Vaccine|September 10, 2009
Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infectionJames F Cummings, Michele D Spring, Robert J Schwenk, et al.
Plos One|April 25, 2009
Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02AMichele D Spring, James F Cummings, Christian F Ockenhouse, et al.
Plos One|January 24, 2008
Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trialMahamadou A Thera, Ogobara K Doumbo, Drissa Coulibaly, et al.
Plos One|February 9, 2010
Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trialMahamadou A Thera, Ogobara K Doumbo, Drissa Coulibaly, et al.
The New England Journal of Medicine|September 16, 2011
A field trial to assess a blood-stage malaria vaccineMahamadou A Thera, Ogobara K Doumbo, Drissa Coulibaly, et al.
Pageof 7